Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 7 of 1,261
  1. WO 2026006232

    COMPOSITION EFFERVESCENTE ORALE

    BAYER HEALTHCARE LLC [US] · Granted Jan 2, 2026 · Expires Dec 28, 2045

    granted
  2. WO 2026006805

    COMPOSÉS À NOYAU À 6 CHAÎNONS UTILISÉS COMME MODULATEURS DE L'HÉLICASE À ADN RECQ DU SYNDROME DE WERNER ET LEURS UTILISATIONS

    AMGEN INC [US] · Granted Jan 2, 2026 · Expires Dec 28, 2045

    granted
  3. US 20260001878

    SUBSTITUTED PYRROLOPYRIDINE COMPOUNDS USEFUL AS INHIBITORS OF TLR9

    BRISTOL MYERS SQUIBB CO [US] · Granted Jan 1, 2026 · Expires Dec 27, 2045

    granted
  4. EP 4670742

    ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE

    ABBVIE INC [US] · Granted Dec 31, 2025 · Expires Dec 26, 2045

    granted
  5. WO 2025264662

    COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UN MÉLANOME

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  6. WO 2025265012

    COMPOSITIONS COMPRENANT DES ANTICORPS ANTI-PCSK9

    AMGEN INC [US] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  7. WO 2025265110

    COMPOSITIONS PHARMACEUTIQUES ORALES RENFERMANT UN COMPOSÉ DE NAPHTYRIDINE

    AMGEN INC [US] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  8. WO 2025262460

    COMPOSITIONS LIPIDIQUES POUR L'ADMINISTRATION D'ACIDES NUCLÉIQUES

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  9. WO 2025262150

    MOLÉCULES DE RECRUTEMENT D'ANTICORPS

    ABLYNX NV [BE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  10. WO 2025260285

    CONJUGUÉ ANTICORPS-MÉDICAMENT

    DUALITY BIOLOGICS SUZHOU CO LTD [CN] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  11. WO 2025261607

    PARTICULES, COMPOSITIONS ET PROCÉDÉS

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  12. WO 2025261951

    POLYTHÉRAPIE AVEC UN ANTICORPS ANTI-CA19-9 ET DU FOLFIRINOX DANS LE TRAITEMENT DU CANCER

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  13. WO 2025262130

    CONJUGUÉ ANTICORPS-MÉDICAMENT

    BIONTECH SE [DE] · Granted Dec 26, 2025 · Expires Dec 21, 2045

    granted
  14. US 2025388678

    Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

    ASTRAZENECA AB [SE] · Granted Dec 25, 2025 · Expires Dec 20, 2045

    granted
  15. WO 2025259831

    FORMES CRISTALLINES D'UN ANTAGONISTE DE LPA1

    BRISTOL MYERS SQUIBB CO [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  16. US 2025382344

    Soluble GLP1/GIP/NPY2 Receptor Triple Agonists

    BOEHRINGER INGELHEIM INT GMH [DE] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  17. WO 2025257278

    SÉQUENCES IMMUNOGÈNES

    BOEHRINGER INGELHEIM INT [DE] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  18. WO 2025259515

    POLYTHÉRAPIE

    AMGEN INC [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  19. WO 2025256977

    NOUVELLES ENZYMES DE CLIVAGE IGM ET IGG

    BAYER AG [DE] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  20. WO 2025257199

    THÉRAPIES POUR LE TRAITEMENT DE PLAIES

    ASTRAZENECA AB [SE] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  21. WO 2025259749

    FRAGMENTS VARIABLES À CHAÎNE UNIQUE STABLES

    AMGEN INC [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  22. WO 2025260042

    CONSTRUCTIONS D'ARNI ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE CNR1

    AMGEN INC [US] · Granted Dec 18, 2025 · Expires Dec 13, 2045

    granted
  23. WO 2025252599

    COMPOSÉS ACTIVATEURS DE CANAUX POTASSIQUES KV7.2/KV7.3

    ANGELINI PHARMA S P A [IT] · Granted Dec 11, 2025 · Expires Dec 6, 2045

    granted
  24. WO 2025252204

    DISPERSIONS SOLIDES AMORPHES D'UN INHIBITEUR DE BRAF

    BEIGENE SUZHOU CO LTD [CN] · Granted Dec 11, 2025 · Expires Dec 6, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.